Medicine
Natacyn 50 mg/mL ophthalmic suspension
Natacyn 50 mg/mL ophthalmic suspension is a prescription medicine containing Natamycin for ophthalmic use, marketed by Harrow Eye, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store between 2°C to 24°C (36°F-75°F).
Key facts
- Active ingredient (INN)
- Natamycin
- Brand
- Natacyn
- Strength
- 50 mg/mL
- Dosage form
- Ophthalmic suspension
- Route
- Ophthalmic
- Packs
- 1 bottle
- Marketing authorisation holder
- Harrow Eye
- Manufacturer
- Harrow Eye2 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store between 2°C to 24°C (36°F-75°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A01AB10 Natamycin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 June 2021
- Identifiers
- RxCUI 204451, 207100DailyMed set ID 20ede08c-0d39-dc65-e063-6394a90aa3e0, 2818fcb8-5bac-41fb-864e-3b598308a428NDC 82667-012, 71776-005Application NDA050514
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle, glass in 1 carton / 15 mL in 1 bottle, glass | 82667-012-05 | Harrow Eye | 1 November 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 October 1978 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Natamycin is a polyene antimicrobial indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. It is available as ophthalmic suspension. MedsAcross supplies Natamycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about NatamycinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- NATACYN prescribing information (Eyevance Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Natacyn 50 mg/mL ophthalmic suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.